CARMA™ News & More

CARMA™ News

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform
May 8, 2019
Read Full Release »

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing
May 1, 2019
Read Full Release »

MaxCyte to Present on CARMA™ Platform at Two Upcoming Industry Conferences in Europe
March 18, 2019
Read Full Release »

MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019
December 19, 2018
Read Full Release »

MaxCyte to Present on CARMA™ Platform at BIO-EUROPE®
October 30, 2018
Read Full Release »

MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors
October 10, 2018
Read Full Release »

MaxCyte, Inc. to Present on CARMA™ Platform at Two Upcoming Industry Conferences
August 29, 2018
Read Full Release »

MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program
16 July 2018
Read Full Release »

MaxCyte, Inc. to Present at 2018 BIO International Convention
May 29, 2018
Read Full Release »

MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer
April 25, 2018
Read Full Release »

MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month
March 12, 2018
Read Full Release »

MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting
March 2, 2017
Read Full Release »

MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies
December 21, 2016
Read Full Release »

MaxCyte Appoints Executive Vice President, Business and Strategic Development
November 2, 2016
Read Full Release »

MaxCyte and The Johns Hopkins Kimmel Cancer Center Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies
April 21, 2015
Read Full Release »

CARMA Scientific Publications

Development of anti-human mesothelin-targeted chimeric antigen receptor (CAR) messenger RNA (mRNA)-transfected peripheral blood lymphocytes (CARMA-hMeso) for ovarian cancer therapy
Human Gene Therapy
2018 Jan 15. doi: 10.1089/hum.2017.080

2017 AACR Annual Meeting Abstract: Development of anti-human mesothelin chimeric antigen receptor (CAR) messenger RNA (mRNA) transfected peripheral blood mononuclear cells (CARMA) for the treatment of mesothelin-expressing cancers

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo